American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Edited by 4th edition with text revision. Washington, DC: American Psychiatric Press; 2013.
2.
BenarousX, ConsoliA, GuiléJM, Garny de La RivièreS, CohenD, OlliacB: Evidence-based treatments for youths with severely dysregulated mood: A qualitative systematic review of trials for SMD and DMDD. Eur Child Adolesc Psychiatry, 26:5–23, 2017.
3.
BlairRJR: The neurobiology of impulsive aggression. J Child Adolesc Psychopharmacol, 26:4–9, 2016.
4.
BlanpiedTA, ClarkeRJ, JohnsonJW: Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci, 25:3312–3322, 2005.
5.
ChangC, RamphulK: AmantadineStatPearls. 2019. Available at: www.ncbi.nlm.nih.gov/pubmed/29763128 (accessed September20, 2019).
6.
CorrellCU: Metabolic side effects of second-generation antipsychotics in children and adolescents: A different story?. J Clin Psychiatry, 66:1331–1332, 2005.
7.
Costa-NunesJ, ZubarevaO, Araújo-CorreiaM, ValençaA, SchroeterCA, PawluskiJL, VignisseJ, SteinbuschH, HermesD, PhillipinesM, SteinbuschHM, StrekalovaT: Altered emotionality, hippocampus-dependent performance and expression of NMDA receptor subunit mRNAs in chronically stressed mice. Stress, 17:108–116, 2014.
8.
DeveneyCM, ConnollyME, HaringCT, BonesBL, ReynoldsRC, KimP, PineDS, LeibenluftE: Neural mechanisms of frustration in chronically irritable children. Am J Psychiatry, 170:1186–1194, 2013.
GiacinoJT, WhyteJ, BagiellaE, KalmarK, ChildsN, KhademiA, EifertB, LongD, KatzDI, ChoS, YablonSA, LutherM, HammondFM, NordenboA, NovakP, MercerW, Maurer-KarattupP, ShererM: Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med, 366:819–826, 2012.
11.
GraciousBL, KrysiakTE, YoungstromEA: Amantadine treatment of psychotropic-induced weight gain in children and adolescents: Case series. J Child Adolesc Psychopharmacol, 12:249–257, 2002.
12.
HammondFM, BickettAK, NortonJH, PershadR: Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil, 29:391–399, 2014.
13.
HammondFM, MalecJF, ZafonteRD, ShererM, BognerJ, DikmenS, WhitneyMP, BellKR, PerkinsSM, MoserEA: Potential impact of amantadine on aggression in chronic traumatic brain injury. J Head Trauma Rehabil, 32:308–318, 2017.
14.
HoffmanL, RiceT, ProutT: Manual for Regulation-Focused Psychotherapy for Children with Externalizing Behaviors (RFP-C): A Psychodynamic Approach. New York (New York), Routledge, 2015.
15.
HosenbocusS, ChahalR: Amantadine: A review of use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry, 22:55–60, 2013.
16.
JohnsonK, McGuinnessTM: Disruptive mood dysregulation disorder: A new diagnosis in the DSM-5. J Psychosoc Nurs Ment Health Serv, 52:17–20, 2014.
17.
KingBH, WrightDM, SnapeM, DourishCT: Case series: Amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. J Am Acad Child Adolesc Psychiatry, 40:654–657, 2001.
18.
KrausMF, MakiPM: Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review. J Neuropsychiatry Clin Neurosci, 9:222–230, 1997.
19.
LeePR, BradyD, KoenigJI: Corticosterone alters N-methyl-D-aspartate receptor subunit mRNA expression before puberty. Brain Res Mol Brain Res, 115:55–62, 2003.
20.
LeibenluftE, StoddardJ: The developmental psychopathology of irritability. Dev Psychopathol, 25:1473–1487, 2013.
21.
MaayanL, CorrellCU: Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol, 21:517–535, 2011.
22.
MarguliesDM, WeintraubS, BasileJ, GroverPJ, CarlsonGA: Will disruptive mood dysregulation disorder reduce false diagnosis of bipolar disorder in children?. Bipolar Disord, 14:1–2, 2012.
23.
McGraneIR, LovelandJG, ZaluskiHJ: Adjunctive amantadine treatment for aggressive behavior in children: A series of eight cases. J Child Adolesc Psychopharmacol, 26:935–938, 2016.
24.
Ter MorsBJ, BackxAPM, SpauwenP, PondsRWHM, Van HartenPN, Van HeugtenCM: Efficacy of amantadine on behavioural problems due to acquired brain injury: A systematic review. Brain Inj, 33:1137–1150, 2019.
25.
TiroshA, ShaiI, AfekA, Dubnov-RazG, AyalonN, GordonB, DerazneE, TzurD, ShamisA, VinkerS, RudichA: Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med, 364:1315–1325, 2011.
26.
TourianL, LeBoeufA, BretonJJ, CohenD, GignacM, LabelleR, GuileJM, RenaudJ: Treatment options for the cardinal symptoms of disruptive mood dysregulation disorder. J Can Acad Child Adolesc Psychiatry, 24:41–54, 2015.
